167 related articles for article (PubMed ID: 16400745)
1. Cancer risk with topical pimecrolimus and tacrolimus.
Prescrire Int; 2005 Dec; 14(80):223. PubMed ID: 16400745
[TBL] [Abstract][Full Text] [Related]
2. Association between exposure to topical tacrolimus or pimecrolimus and cancers.
Hui RL; Lide W; Chan J; Schottinger J; Yoshinaga M; Millares M
Ann Pharmacother; 2009 Dec; 43(12):1956-63. PubMed ID: 19903860
[TBL] [Abstract][Full Text] [Related]
3. Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma.
Schneeweiss S; Doherty M; Zhu S; Funch D; Schlienger RG; Fernandez-Vidaurre C; Seeger JD
Dermatology; 2009; 219(1):7-21. PubMed ID: 19293564
[TBL] [Abstract][Full Text] [Related]
4. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?
Ormerod AD
Br J Dermatol; 2005 Oct; 153(4):701-5. PubMed ID: 16181449
[No Abstract] [Full Text] [Related]
5. [Topical immunomodulators, such as tacrolimus and pimecrolimus, in the treatment of atopic dermatitis].
van der Laan JR
Ned Tijdschr Geneeskd; 2005 Aug; 149(32):1816; author reply 1817. PubMed ID: 16121669
[No Abstract] [Full Text] [Related]
6. Clinical inquiries. What is the role of tacrolimus and pimecrolimus in atopic dermatitis?
Trammell S; Shakil A; Wilder L; Daugird A
J Fam Pract; 2005 Aug; 54(8):714-6. PubMed ID: 16061062
[No Abstract] [Full Text] [Related]
7. [Letter: Tinea faciei exacerbated by topical immunomodulation: Two case reports].
Ruiz-Villaverde R; Sanchez-Cano D
Dermatol Online J; 2010 Mar; 16(3):14. PubMed ID: 20233571
[TBL] [Abstract][Full Text] [Related]
8. Eczema drugs tacrolimus (Protopic) and pimecrolimus (Elidel): cancer concerns.
Wooltorton E
CMAJ; 2005 Apr; 172(9):1179-80. PubMed ID: 15817641
[No Abstract] [Full Text] [Related]
9. Pimecrolimus and tacrolimus: the US FDA public health advisory.
Maddin S
Skin Therapy Lett; 2005 May; 10(4):1-3. PubMed ID: 15986080
[No Abstract] [Full Text] [Related]
10. Topical tacrolimus and pimecrolimus: cancer, infections.
Prescrire Int; 2010 Nov; 19(110):257. PubMed ID: 21298814
[No Abstract] [Full Text] [Related]
11. Topical immunosuppressants, genital lichen sclerosus and the risk of squamous cell carcinoma: a case report.
Fischer G; Bradford J
J Reprod Med; 2007 Apr; 52(4):329-31. PubMed ID: 17506377
[TBL] [Abstract][Full Text] [Related]
12. [Topical pimecrolimus and tacrolimus and the risk of cancer].
Sánchez-Pérez J
Actas Dermosifiliogr; 2007 Jun; 98(5):312-7. PubMed ID: 17555673
[TBL] [Abstract][Full Text] [Related]
13. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force.
Berger TG; Duvic M; Van Voorhees AS; VanBeek MJ; Frieden IJ;
J Am Acad Dermatol; 2006 May; 54(5):818-23. PubMed ID: 16635663
[No Abstract] [Full Text] [Related]
14. Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology.
Fonacier L; Spergel J; Charlesworth EN; Weldon D; Beltrani V; Bernhisel-Broadbent J; Boguniewicz M; Leung DY; ;
J Allergy Clin Immunol; 2005 Jun; 115(6):1249-53. PubMed ID: 15940142
[No Abstract] [Full Text] [Related]
15. [Topical immune modulation and risk of cancer].
Deleuran M; Zachariae C; Thestrup-Pedersen K
Ugeskr Laeger; 2009 Aug; 171(35):2468-71. PubMed ID: 19732533
[TBL] [Abstract][Full Text] [Related]
16. Topical tacrolimus plus oral alcohol: skin irritation.
Prescrire Int; 2007 Dec; 16(92):249. PubMed ID: 18092421
[TBL] [Abstract][Full Text] [Related]
17. Topical pimecrolimus and tacrolimus do not accelerate photocarcinogenesis in hairless mice after UVA or simulated solar radiation.
Lerche CM; Philipsen PA; Poulsen T; Wulf HC
Exp Dermatol; 2009 Mar; 18(3):246-51. PubMed ID: 19183401
[TBL] [Abstract][Full Text] [Related]
18. [Pimecrolimus (SDZ ASM 981). Current state of research].
Dissemond J; Goos M; Wagner SN
Dtsch Med Wochenschr; 2002 May; 127(22):1199-203. PubMed ID: 12035117
[No Abstract] [Full Text] [Related]
19. An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance.
Langley RG; Luger TA; Cork MJ; Schneider D; Paul C
Dermatology; 2007; 215 Suppl 1():27-44. PubMed ID: 18174691
[TBL] [Abstract][Full Text] [Related]
20. A case of cheilitis glandularis superimposed on oral lichen planus: successful palliative treatment with topical tacrolimus and pimecrolimus.
Erkek E; Sahin S; Kilic R; Erdogan S
J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):999-1000. PubMed ID: 17659026
[No Abstract] [Full Text] [Related]
[Next] [New Search]
